| References | Diabetic animal model | Administration of BBR |
Tissues examined | Effects of BBR |
Oxidative stress markers |
Antioxidant enzymes | MDA | GSH | SOD | GSH-Px |
| [27] | Wistar rats, STZ 60 mg/kg, single i.p. injection | 200 mg/kg/d, p.o. for 12 weeks | Serum | | ND | | ND |
| [28] | SD rats, STZ 60 mg/kg, single tail vein injection | 200 mg/kg/d, p.o. for 12 weeks | Serum | | ND | | ND |
| [29] | Wistar rats, STZ 35 mg/kg, single i.p. injection, HFD for 14 weeks after 2 weeks on diabetes | 75, 150, and 300 mg/kg/d, p.o. for 16 weeks | Serum and liver | | ↑ | | |
| [30] | ddY mice, STZ 100 mg/kg, single i.p. injection | 200 mg/kg/d, p.o. for 2 weeks | Liver | ND | ↓ | | |
| [31] | SD rats, HFD for 2 weeks, then STZ 35 mg/kg, single i.p. injection | 50, 100, and 150 mg/kg/d, p.o. for 6 weeks | Liver | — | — | — | ND |
| [32] | ICR mice, nicotinamide 1000 mg/kg + STZ 100 mg/kg, single i.p. injection | 100 mg/kg/d, p.o. for 2 weeks | Liver and kidney | | ND | | ND |
| [33] | SD rats, HFD for 4 weeks, then STZ 40 mg/kg, single i.p. injection, HFD for another 8 weeks | 100 and 200 mg/kg/d, p.o. for 8 weeks | Kidney | | ND | | ND |
| [34] | Wistar rats, STZ 35 mg/kg, single i.p. injection, HFD for 14 weeks after 2 weeks on diabetes | 75, 150 and 300 mg/kg/d, p.o. for 16 weeks | Pancreas | | ND | | ND |
| [35] | Wistar rats, alloxan 55 mg/kg, single tail vein injection, then on HFD | 100 and 200 mg/kg/d, p.o. for 21 days | Heart | | ND | | |
| [36] | Wistar rats, STZ 60 mg/kg, single i.p. injection | 25, 50, and 100 mg/kg/d, p.o. for 30 days | Cortex and hippocampus | | | ND | ND |
| [37] | Wistar rats, STZ 55 mg/kg, single i.p. injection | 50 and 100 mg/kg/d, p.o. for 8 weeks | Hippocampus | | ND | | ND |
|
|
: decrease, : increase, ND: not determined, —: no effect; BBR: berberine, MDA: malondialdehyde, GSH: glutathione, SOD: superoxide dismutase, GSH-Px: glutathione peroxidase, STZ: streptozotocin, p.o.: per os/oral administration, i.p.: intraperitoneal, HFD: high fat diet.
|